Radiolabeling of Nanoparticles

Zhang, Zhiyong

doi:10.1002/9783527689125.ch4

Cited by 1 publication

(7 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the methods of indirect radiolabeling, exogenous coordination chemistry moieties, namely BFCs and prosthetic groups, are employed to conjugate an MNP for labeling with a radionuclide through chemical linkers (Brechbiel, 2008; Z. Zhang, 2016). By selecting a proper BFC or prosthetic group, indirect radiolabeling is a simple approach that has been commonly used.…”

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

“…BFCs are molecules consisting of a metal chelating unit and a reactive functionality (Lattuada, Barge, Cravotto, Giovenzana, & Tei, 2011). While the former binds to metallic radionuclides, the latter has been covalently conjugated to the surface of MNPs (Z. Zhang, 2016). Conjugation of BFCs to the MNP usually requires surface modification by attaching carboxyl, thiol, or amino groups to the MNP surface.…”

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

“…A technique to minimize this problem is by employing nonmetallic radionuclides instead of metallic radionuclides (Ge et al, 2019). The most common nonmetallic radioisotopes which are covalently bound to MNPs through prosthetic groups are 11 C (R. Sharma et al, 2013), 14 C (Nallathamby et al, 2015), 18 F (S. Rojas et al, 2012), 123 I (Z. Zhang, 2016), 124 I (J. Lee et al, 2013), 125 I (Jang et al, 2012; S. Liu et al, 2009; Y. Tang et al, 2015), and 131 I (L. X. Liu et al, 2016).…”

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

“…Radiochemical doping refers to a direct radiolabeling process that the radionuclide is incorporated into its cold counterpart or surrogate of the reagents for the synthesis of MNPs, which results in intrinsically radioactive MNPs with high radiolabeling yield and stability (Goel et al, 2014; Peltek et al, 2019; Z. Zhang, 2016). Although this method forms highly stable radioactive MNPs, the increased radiation exposure during their production is a significant working hazard (X.…”

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

“…Since the exchange is proportional to their molar ratio, this technique results in lower specific activity. In other words, when high specific activity is required for imaging or therapy, this method is not an option (Z. Zhang, 2016). To date, a few MNP systems have been radiolabeled by this approach (Hildebrand & Franke, 2012; Hildebrand et al, 2015; Hoffman et al, 2014).…”

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

See 4 more Smart Citations

Radiolabeling strategies and pharmacokinetic studies for metal based nanotheranostics

Bahadori

Mulgaonkar

Hart

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Radiolabeled metal‐based nanoparticles (MNPs) have drawn considerable attention in the fields of nuclear medicine and molecular imaging, drug delivery, and radiation therapy, given the fact that they can be potentially used as diagnostic imaging and/or therapeutic agents, or even as theranostic combinations. Here, we present a systematic review on recent advances in the design and synthesis of MNPs with major focuses on their radiolabeling strategies and the determinants of their in vivo pharmacokinetics, and together how their intended applications would be impacted. For clarification, we categorize all reported radiolabeling strategies for MNPs into indirect and direct approaches. While indirect labeling simply refers to the use of bifunctional chelators or prosthetic groups conjugated to MNPs for post‐synthesis labeling with radionuclides, we found that many practical direct labeling methodologies have been developed to incorporate radionuclides into the MNP core without using extra reagents, including chemisorption, radiochemical doping, hadronic bombardment, encapsulation, and isotope or cation exchange. From the perspective of practical use, a few relevant examples are presented and discussed in terms of their pros and cons. We further reviewed the determinants of in vivo pharmacokinetic parameters of MNPs, including factors influencing their in vivo absorption, distribution, metabolism, and elimination, and discussed the challenges and opportunities in the development of radiolabeled MNPs for in vivo biomedical applications. Taken together, we believe the cumulative advancement summarized in this review would provide a general guidance in the field for design and synthesis of radiolabeled MNPs towards practical realization of their much desired theranostic capabilities. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Diagnostic Tools > Diagnostic Nanodevices Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%

Section: Radiolabeling Of Mnpsmentioning

confidence: 99%